维普中文期刊产品整合服务
18篇 您的检索式:作者名="Hart DP"
    题名 作者 年代 出处 被引量
1Dose-escalated donor lymphocyte infusions following reduced intensity transplantation:toxicity,chimerism,and disease responses显示文摘Peggs KS Thomson K Hart DP 2004Blood2004,103,4:1
2Pectoralis Major Tendon Rupture:A Biomechanical Analysis of Repair Techniques显示文摘Hart ND Lindsey DP McAdams TR 0,,11:1
3Dose-escalated donor lym-phocyte infusions following reduced intensity transplantation:toxicity,chimerism,and disease responses显示文摘Peggs KS Thomson K Hart DP 2004Blood2004,103,:1
4Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses显示文摘Peggs KS Thomson K Hart DP 2004Blood2004,103,:1
5Current status of allogeneic stem cell transplantation for treatment of hematologic malignancies显示文摘Hart DP Peggs KS 2007Clin Pharmacol Ther2007,82,3:1
6Use of ^18F - FDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions显示文摘Hart DP Avivi I Thomson KJ 2005Br J Haematol2005,128,6:1
7Current status of allogeneic stem cell transplantation for treatment of hematologic malignancies显示文摘Hart DP Peggs KS 0,,03:1
8Endophthalmitis: a review of current evaluation and management显示文摘Lemley CA Hart DP 2007Retina2007,27,6:1
9Current status of mlogeneic stem celltransplantation for treatment of hematologic malignancies 显示文摘Hart DP Peggs KS 2007Clin Pharmacol Ther2007,82,:1
10The use of topical aqueous suppressants in the prevention of postoperative intraocular pressure elevation after pars plana vit- rectomy with long-acting gas tamponade 显示文摘Mittra RA Pollack JS Dev S Hart DP Mieler WF Pulido JS 2000Ophthalmology2000,107,3:1
11Dose-escalated donor lymphocyte infusions following reduced intensity transplantation:toxicity,chimerism,and disease responses显示文摘Peggs KS Thomson K Hart DP 2004Blood2004,103,4:1
12Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial显示文摘Jacoba van der Zee Dionisio González Gerard C van Rhoon Jan DP van Dijk Wim LJ van Putten Augustinus AM Hart 2000The Lancet2000,,9210:1
13Endophthalmitis: a review of current evaluation and management显示文摘Lemley CA Hart DP 2007Retina2007,27,6:1
14Polo-like kinasel is overexpreased in colorectal cancer and participates in the migration and invasion of colorectal cancercells显示文摘Hart DP Zhu QL Cui JT 2012Med Sci Monlt2012,18,6:1
15Vascular and brain neurop eptide Y in banded and spontaneously hypertensive rats显示文摘Morris MJ Tortelli CF Hart DP 2004Peptides2004,25,8:1
16The human papillomavirus type 16 E6 and E7 oncoproteins dissociate cellular telomerase activity from the maintenance of telomere lengh 显示文摘Stoppler H Hart Mann DP Sherman L 1997J Biol Chem1997,272,13:1
17Use of 18F -FDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions显示文摘Hart DP Avivi I Thomson KJ 2005Br J Haematol2005,128,6:1
18ASCL1调节胚胎和成人脊髓中NG2胶质细胞的增殖显示文摘NG2胶质细胞是高度增殖的少突胶质细胞的前体细胞(OPCs),广泛分布于整个中枢神经系统(CNS)。在发育过程中,NG2-glia主要分化为少突胶质细胞(OL)迁移至髓鞘轴突纤维,但它们也可作为OPCs保留在成熟的CNS中。有趣的是,灰质(GM)中的NG2胶质细胞在增殖、分化、基因表达和电生理学特性方面与白质(WM)中的NG2胶质细胞有着本质上的不同。本文研究转录调节因子ASCL1在控制GM和WM中NG2胶质细胞分布和发育中的作用。在脊髓中,WM的NG2胶质细胞中ASCL1水平高于GM中的水平。WM和GM的NG2胶质细胞中ASCL1的这种差异水平维持到成人阶段。长期克隆谱系分析显示,即使它们经历广泛增殖以在脊髓中产生大的OLs簇,单个ASCL1+少突胶质细胞祖细胞(OLP)和NG2胶质细胞的后代仍主要限于GM或WM。特异性地在胚胎或成年脊髓中的NG2胶质细胞中条件性删除Asc1导致这些细胞的增殖显著减少,并非分化减少。这些发现表明,ASCL1是CNS中NG2胶质细胞增殖特性的内在调节因子。Kelenis DP Hart E Edwards-Fligner M Johnson JE Vue TY 聂昊(编译) 2019神经损伤与功能重建2019,14,1:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费